BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. Highlights, including post period: · Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a · Site activation of Ph2a in US and Europe proceeding well · Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for